Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet-induced obesity.

AIMS

Obesity increases the risk of heart failure with preserved (HFpEF), but not reduced ejection fraction (HFrEF). The glucagon-like peptide-1 receptor agonist (GLP-1-RA) semaglutide improves outcome of patients with obesity with or without HFpEF, while GLP-1-RAs were associated with adverse outcome in patients with HFrEF. Here, we investigate the effect of in vivo treatment with semaglutide on excitation-contraction coupling in a rat model of obesity.

METHODS AND RESULTS

Rats received high-fat/high-fructose diet for 8 weeks and were then randomized to semaglutide (HFD/Sema) or vehicle (HFD/Veh) for another 8 weeks, during which they could choose between HFD and a low-fat/high-fructose diet (LFD). Control rats received either standard chow (CON), HFD or LFD only, without treatment. After 16 weeks, sarcomere shortening and cytosolic Ca concentrations ([Ca]) were determined in isolated cardiomyocytes. Compared with CON, HFD/Veh increased the amplitude of [Ca] transients and systolic sarcomere shortening in absence or presence of β-adrenergic stimulation, which was reversed by HFD/Sema. Caffeine-induced sarcoplasmic reticulum (SR) Ca release and L-type Ca channel (LTCC) currents were reduced by HFD/Sema versus HFD/Veh, while SR Ca ATPase activity remained unaffected. Compared with HFD, LFD increased [Ca] transients and sarcomere shortening further despite similar effects on body weight.

CONCLUSIONS

While HFD increased cardiomyocyte [Ca] transients and systolic sarcomere shortening, semaglutide normalized these alterations, mediated by reduced SR Ca load and LTCC currents. Because increased LTCC currents were previously traced to cardiac hypertrophy, these effects may explain why GLP-1-RAs provide benefits for patients with obesity with or without HFpEF, but rather adverse outcome in HFrEF.